<DOC>
	<DOCNO>NCT00457392</DOCNO>
	<brief_summary>This study test whether treatment erlotinib plus SU011248 good erlotinib alone patient advanced/metastatic lung cancer receive previous treatment platinum-based regimen .</brief_summary>
	<brief_title>A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients locally advanced/metastatic nonsmall cell lung cancer Prior treatment 2 chemotherapy regimen include platinumbased regimen Prior treatment receptor tyrosine kinase inhibitor , VEGF inhibitor ( exception bevacizumab ) angiogenesis inhibitor History know brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>erlotinib</keyword>
	<keyword>Phase 3</keyword>
</DOC>